首页|效率医疗背景下靶向药物皮下制剂在乳腺癌患者中的应用及展望

效率医疗背景下靶向药物皮下制剂在乳腺癌患者中的应用及展望

Application and prospect of targeted drug subcutaneous preparations in breast cancer patients under the background of efficiency medicine

扫码查看
近年来随着皮下给药制剂工艺的发展,越来越多的抗肿瘤靶向静脉剂型获批皮下制剂.在效率医疗背景下,靶向药物皮下注射剂型革新了人表皮生长因子受体-2(HER-2)阳性乳腺癌的治疗模式,将为乳腺癌患者提供更加便捷、高效和安全的个体化治疗新选择.本文综述了乳腺癌靶向药物皮下注射剂型的概念、机制及注意事项,以及该剂型在乳腺癌患者靶向治疗中的实践效果,并探讨了靶向药物皮下注射剂型在国内的应用前景与展望,以期为推动靶向药物皮下注射剂型在国内乳腺癌患者中的应用提供参考及借鉴.
In recent years,with the development of subcutaneous drug delivery technology,more and more anti-tumor targeted intravenous formulations have been approved for subcutaneous preparation.In the context of efficient medical treatment,targeted drug subcutaneous injection has innovated the treatment mode of human epidermal growth factor receptor-2(HER-2)positive breast cancer,which will provide more convenient,efficient and safe personalized treatment options for breast cancer patients.This article reviewed the concept,mechanism and precautions of the subcutaneous injection of targeted drugs for breast cancer,as well as the practical effect of this dosage form in the targeted treatment of breast cancer patients,and discussed the application prospects and prospects of the subcutaneous injection of targeted drugs in China,with a view to providing reference and reference for promoting the application of the subcutaneous injection of targeted drugs in domestic breast cancer patients.

Breast cancerHuman epidermal growth factor receptor-2(HER-2)Targeted subcutaneous preparationsTargeted therapy

汪洋、孙蓓、李梦奇、孙英明、李珂

展开 >

300060 天津市肿瘤防治重点实验室天津市恶性肿瘤临床医学研究中心

300211 天津医科大学第二医院肿瘤科

乳腺癌 人表皮生长因子受体-2(HER-2) 靶向皮下制剂 靶向治疗

天津市医学重点学科(专科)建设项目精准医学研究与产业创新发展基金天津医科大学医院管理创新研究项目

TJYXZDXK-011ASIMQ59-82024YG13

2024

临床肿瘤学杂志
解放军第八一医院

临床肿瘤学杂志

CSTPCD
影响因子:1.583
ISSN:1009-0460
年,卷(期):2024.29(5)
  • 3